| Shuai Lixiong,Cao Zhifei,Zhang Yongsheng.Strategy and progress of stereotactic body radiotherapy for renal cell carcinoma[J].Chinese Journal of Radiological Medicine and Protection,2023,43(11):929-933 |
| Strategy and progress of stereotactic body radiotherapy for renal cell carcinoma |
| Received:June 13, 2023 |
| DOI：10.3760/cma.j.cn112271-20230613-00191 |
| KeyWords:Renal cell carcinoma Stereotactic body radiotherapy Immunotherapy |
| FundProject:国家自然科学基金面上项目(12275192) |
|
| Hits: 557 |
| Download times: 271 |
| Abstract:: |
| Renal cell carcinoma (RCC) is one of the most aggressive malignancies in the genitourinary system with a poor prognosis, especially in patients with RCC who have metastases. RCC is conventionally considered not sensitive to radiotherapy. Compared with conventional radiotherapy, stereotactic body radiotherapy (SBRT) has the characteristics of higher precision, higher irradiation dose, and less damage to the surrounding tissue. In recent years, SBRT has shown definite efficacy in the treatment of primary and advanced metastatic RCC. SBRT combined with targeted therapy and immunotherapy can improve the local tumor control rate and cause fewer adverse reactions in patients with primary and advanced metastatic RCC. This article reviews the literature on the strategy and progress of SBRT in combination with targeted therapy and immunotherapy. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
